Royal Jelly
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Compound Class | A whole biological matrix — hypopharyngeal and mandibular gland secretion of Apis mellifera nurse bees. No CAS |
| Signature Marker | 10-HDA (10-hydroxy-trans-2-decenoic acid) — unique to royal jelly; typically ~1–2% of fresh material |
| Other Components | Major royal jelly proteins (MRJPs, incl. royalactin), 10-hydroxydecanoic acid, trans-2-decenoic acid, pantothenic acid, sugars, water |
| Typical Standardisation | 10-HDA by HPLC — the accepted authenticity and quality marker (commonly ≥4–6% in dried powder) |
| ⚠ CRITICAL SAFETY | Royal jelly causes anaphylaxis, including fatalities. Documented asthma and anaphylaxis; a major allergen requiring prominent declaration |
| Primary Applications | Bone density (postmenopausal); menopausal symptoms; endothelial function; general tonic |
| Claim Strength (Overview) | Emerging — small trials across scattered endpoints; the safety signal is better established than any efficacy signal |
| Buy from Herbuno | Royal Jelly Powder → |
Safety first, because it governs everything else on this page: royal jelly is a documented cause of anaphylaxis, including fatal anaphylaxis, and of acute asthma and contact dermatitis. This is not a precautionary theoretical warning appended out of caution — it is a well-characterised clinical phenomenon with a case literature going back to the 1990s. Any formulator working with royal jelly must treat allergen declaration as the first design requirement, not the last. Name origin: Royal jelly is the secretion of the hypopharyngeal and mandibular glands of nurse honeybees, fed to all larvae briefly and to the queen larva exclusively and continuously — and that dietary difference alone is what makes a queen rather than a worker, from a genetically identical egg. It is one of the more striking examples of nutritional epigenetics in biology, and it is also the source of most of the mythology surrounding the ingredient. Traditional use: Royal jelly has been used as a tonic in Chinese and Japanese practice and is widely consumed in Japan today. Research trajectory: Work has centred on 10-HDA — a fatty acid found nowhere else in nature, which serves as the authenticity marker — and on the major royal jelly proteins, particularly royalactin, proposed as the queen-determining factor.
Evidence for Royal Jelly Applications
The allergy literature is the most robust body of evidence on this compound and must lead. A clinical series characterised royal-jelly-induced asthma and anaphylaxis with immunologic correlations, establishing IgE-mediated sensitisation as the mechanism (Leung 1995). Case reports have continued to accumulate: a 26-year-old woman developed anaphylaxis after a crude royal jelly beverage, confirmed by positive prick test to royal jelly with negative tests in healthy volunteers and no reaction to honey — with the authors explicitly warning that increased consumption of royal jelly in health-food supplements may increase the incidence of royal-jelly-related allergic reactions (Katayama 2008). Note that reaction occurred without honey reactivity — royal jelly sensitisation is distinct. Claim strength: High.
The efficacy evidence, by contrast, is thin and scattered across unrelated endpoints — a pattern that itself should prompt caution. A randomized trial of dried royal jelly capsules (equivalent to 3,000 mg/day fresh) over six months in postmenopausal women reported preservation of femoral bone mineral density and hip structural parameters, whereas the placebo group declined significantly. Randomized work has examined royal jelly for vascular endothelial function in healthy volunteers, and pilot trials have combined it with CoQ10 in swimmers and runners. These are individually reasonable studies. Collectively they do not constitute an evidence base for any single claim, and a formulator should not assemble them into one. Claim strength: Emerging.
10-HDA is the scientifically defensible part of the story and the right thing to specify against. 10-hydroxy-trans-2-decenoic acid is unique to royal jelly — it exists nowhere else in nature, which makes it an excellent authenticity marker — and HPLC analysis has quantified its mass fraction in fresh royal jelly at around 0.92%. It has documented in-vitro antimicrobial and anti-inflammatory activity, and preclinical work has reported inhibition of migration and invasion in colorectal carcinoma cell lines. These are cell-culture findings and should be presented as such; they are not a cancer claim. Claim strength: Emerging (preclinical).
The royalactin and longevity narrative deserves a sceptical rather than a credulous treatment. The queen-determining protein royalactin, the major royal jelly proteins, 10-HDA and pantothenic acid have all been proposed as mediators of a longevity effect, and rodent work found that royal jelly increased average survival time at some doses — but notably did not extend total lifespan, and the effect was non-monotonic across dose. In C. elegans, royal jelly and 10-HDA increased lifespan. This is interesting invertebrate and rodent biology. Translating "makes a bee larva into a queen" into a human anti-ageing claim is a category error, and the market makes it constantly. Claim strength: Emerging.
Two further practical points. Royal jelly should not be taken with antihypertensive medication without advice, given reported vasodilative and hypotensive activity, and a case of haemorrhagic colitis associated with royal jelly intake has been reported. More broadly: allergic reactions to royal jelly have been observed in relation to sensitisation to Compositae, and individuals with asthma, atopy, or existing bee-product allergy appear to be at elevated risk — several of the reported anaphylaxis cases had a background of asthma and atopic disease. This is a population that overlaps heavily with the health-supplement consumer. Claim strength: Moderate.
Dosage & Formulator Specification
Herbuno carries Royal Jelly Powder. This ingredient carries a documented risk of anaphylaxis, including fatal anaphylaxis. Buyers must treat prominent allergen declaration as a non-negotiable design requirement, and should specify 10-HDA content by HPLC as the authenticity and quality marker. Herbuno will discuss allergen labelling scope at enquiry.
Trial dosing has commonly used dried royal jelly at capsule doses equivalent to around 3,000 mg/day of fresh royal jelly, sustained over six months in the bone-density work. Because fresh and dried material differ roughly threefold in mass, and because 10-HDA content varies substantially with bee nutrition, season and processing, a dose stated in milligrams of powder is close to meaningless without a 10-HDA specification alongside it. Formulators should dose against 10-HDA content, not against gross powder weight, and should state which basis a label figure refers to.
Analytical verification should centre on 10-HDA by HPLC, the accepted authenticity marker, since it occurs nowhere else in nature and its level is the standard quality index (fresh material carries roughly 1–2%; dried powders are commonly specified at ≥4–6%). Fresh-versus-dried basis must be stated explicitly. Major royal jelly protein content and profile is a useful secondary specification. Royal jelly is heat- and light-sensitive and degrades on storage; cold-chain history, water content, and freshness indicators should be documented. Adulteration is a known problem in this category — 10-HDA quantification is the primary defence against it.
Royal jelly is a major allergen and a documented cause of anaphylaxis, including fatalities. Asthma, contact dermatitis, and acute anaphylaxis are all reported, mediated by IgE sensitisation to royal jelly proteins including MRJP3. Reaction can occur without reactivity to honey, so royal jelly sensitisation must be treated as distinct rather than folded into a general bee-product warning. Individuals with asthma, atopy, existing bee-product or Compositae sensitisation appear to be at elevated risk, and several reported cases had exactly that background — a population that overlaps substantially with supplement consumers. Prominent allergen declaration is mandatory. Royal jelly should not be combined with antihypertensive medication without advice given reported hypotensive activity, and a case of haemorrhagic colitis has been reported. Given that the safety signal is considerably better established than any efficacy signal, formulators should think carefully about the risk-benefit case they are asking a consumer to accept.
Frequently Asked Questions — Royal Jelly
Is royal jelly safe?
It carries a documented risk of anaphylaxis, including fatal anaphylaxis, along with acute asthma and contact dermatitis — mediated by IgE sensitisation to royal jelly proteins. This is a well-characterised clinical phenomenon with a case literature going back to the 1990s, not a precautionary warning. Prominent allergen declaration is mandatory.
If someone is fine with honey, are they fine with royal jelly?
No. Royal jelly sensitisation is distinct. In a documented anaphylaxis case, the patient reacted to crude royal jelly with a positive prick test but had no reaction to honey at all. Royal jelly must be treated as its own allergen, not folded into a general bee-product warning.
What is 10-HDA and why specify it?
10-hydroxy-trans-2-decenoic acid — a fatty acid that exists nowhere else in nature, which makes it an excellent authenticity marker and the standard quality index. Fresh royal jelly carries roughly 1-2%; dried powders are commonly specified at 4-6%. Since adulteration is a known problem in this category, 10-HDA quantification is the primary defence.
Does royal jelly extend lifespan?
That claim is a category error the market makes constantly. Royal jelly turns a bee larva into a queen — genuinely remarkable epigenetics. But in rodents it increased average survival at some doses while not extending total lifespan, non-monotonically. Invertebrate and rodent findings do not translate into a human anti-ageing claim.
Related compounds: Polyphenols, Arachidonic Acid, Colostrum, Adenosine
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery